Tempo Therapeutics

Executive Summary

Tempo Therapeutics, headquartered in San Diego, CA, is a privately-held biotechnology and tissue engineering company founded in 2016. The company specializes in developing innovative medical technologies to accelerate patient recovery in surgical oncology and soft tissue reconstruction. By leveraging immunomodulation and advanced material science, Tempo aims to build functional tissue and organs directly within patients, addressing critical unmet needs in regenerative medicine. Their platform combines biocompatible scaffolds with immunomodulatory agents to promote tissue regeneration while minimizing immune rejection. Tempo's approach has the potential to transform outcomes for patients undergoing complex surgeries, such as mastectomy reconstruction or tumor resection, by improving healing and reducing complications. As a private entity with limited public information, the company appears to be in a preclinical or early clinical stage, focusing on proof-of-concept studies and regulatory pathway development. Their strategic location in San Diego's vibrant biotech ecosystem positions them for collaboration and funding opportunities. While specific financial details and pipeline milestones are not disclosed, Tempo's innovative platform could address significant market opportunities in surgical reconstruction and tissue repair.

Upcoming Catalysts (preview)

• Q4 2026Initiation of First-in-Human Clinical Trial for Lead Product Candidate60% success
• Q3 2026Publication of Preclinical Immunomodulation Data in Peer-Reviewed Journal75% success
• Q2 2027Strategic Partnership or Licensing Agreement with Major Medical Device Company35% success